Welcome to our dedicated page for Humana news (Ticker: HUM), a resource for investors and traders seeking the latest updates and insights on Humana stock.
Humana Inc. reports news around its U.S. healthcare business, combining Humana insurance services with CenterWell healthcare services. Company updates commonly address Medicare Advantage and other health plan membership, Insurance segment benefit ratios, GAAP and adjusted earnings, full-year guidance, and capital returns through quarterly dividends.
News also covers CenterWell's senior-focused primary care, home health, pharmacy, hospice and retail pharmacy activities; prescription access and home delivery partnerships; healthcare research tied to medication adherence and chronic disease care; palliative care arrangements; health data interoperability; and board refreshment or other governance actions.
Humana has begun transitioning its Kindred at Home brand to CenterWell Home Health, strengthening its commitment to quality home care. This rebranding effort, initiated on March 1, 2022, will occur across seven states initially, with further expansions planned. The change aims to integrate Kindred's home health services into Humana's overall strategy, enhancing care continuity for patients. CenterWell will serve over 350 locations in 38 states, focusing on improving patient health outcomes and providing personalized care to Medicaid and Medicare patients.
Humana Inc. (NYSE: HUM) has elected David T. Feinberg, M.D., M.B.A., to its Board of Directors. With over 25 years of experience, Feinberg is currently the CEO of Cerner and previously led Google Health, enhancing healthcare initiatives using technology and innovation. Humana's Chairman, Kurt J. Hilzinger, emphasized Feinberg's expertise in improving clinical care and digital transformation as beneficial for the company's growth and strategy execution. This appointment increases Humana's board to 14 members.
Humana Inc. (NYSE: HUM) has announced that Chief Financial Officer Susan M. Diamond will present at the Barclays Global Healthcare Conference on Tuesday, March 15, 2022, at 9:30 a.m. Eastern time. Investors can access a live audio webcast of the presentation on Humana's Investor Relations page. The company emphasizes its commitment to integrated care, aiming to improve the health and well-being of its members while lowering costs. Humana supports healthcare professionals through various clinical capabilities and resources.
Humana Inc. (NYSE: HUM) announced a plan to enhance its Board of Directors by appointing two new independent directors as part of a cooperation agreement with Starboard Value LP. This initiative aims to improve corporate governance and align with the company's growth strategies. Humana reiterated its long-term earnings growth target of 11-15% and a $1 billion value creation goal by 2023, while also focusing on expanding its Medicare Advantage market share and increasing pre-tax margins.
Humana Inc. (NYSE: HUM) has declared a cash dividend of $0.7875 per share, reflecting a 12.5% increase from the previous $0.70 dividend. This dividend is payable on April 29, 2022, to stockholders of record as of March 31, 2022. Humana aims to enhance health outcomes and manage costs through integrated care, benefiting millions of members, including Medicare recipients and military personnel. The company provides a range of resources, such as in-home care and behavioral health services, to simplify healthcare access and improve member well-being.
Humana Inc. (NYSE: HUM), in collaboration with The Humana Foundation and the University of Louisville, announced a $25 million investment in the Health Equity Innovation Hub. This initiative aims to enhance health equity for marginalized populations in Louisville and beyond. The funding includes $1.5 million from Humana and up to $13.5 million from The Humana Foundation, marking one of the largest donations in UofL’s history. The Hub will focus on research, talent development, and entrepreneurship, addressing social determinants of health to improve overall health outcomes.
Humana Inc. (NYSE: HUM) has received notification from the Louisiana Department of Health to award a contract for providing Medicaid coverage in Louisiana. The Medicaid division, Humana Healthy Horizons, plans to commence service later this year, contingent on completing the protest period. The initiative aims to enhance health outcomes for 1.6 million Medicaid beneficiaries in Louisiana through a holistic care approach. This selection underscores Humana's commitment to improving community health and supporting urgent needs through programs addressing social determinants of health.
Humana Inc. (NYSE: HUM) announced that CEO Bruce D. Broussard will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 11:20 a.m. ET. Interested investors can access a live audio webcast on Humana’s Investor Relations page at humana.com. The company emphasizes its commitment to integrated healthcare, aiming to improve health and reduce costs for its members through various services, including in-home care and data analytics.
Summary not available.
Humana Specialty Pharmacy announced the addition of two oncology therapies: TAGRISSO® (osimertinib) for EGFRm non-small cell lung cancer and LENVIMA® (lenvatinib) for various cancers. These drugs will be delivered directly to patients, supported by Humana's Oncology Center of Excellence, which offers expert guidance on treatment. Humana is dedicated to enhancing patient experiences and health outcomes while managing chronic and complex illnesses through personalized services.